{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Islet+Cell+Carcinoma&page=2", "query": { "condition": "Pancreatic Islet Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Islet+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T22:30:55.523Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003514", "title": "Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Merkel Cell Carcinoma", "Islet Cell Carcinoma", "Neuroendocrine Carcinoma", "Pituitary Tumor" ], "interventions": [ { "name": "antineoplaston A10", "type": "DRUG" }, { "name": "antineoplaston AS2-1", "type": "DRUG" }, { "name": "alternative product therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "biologically based therapies", "type": "PROCEDURE" }, { "name": "cancer prevention intervention", "type": "PROCEDURE" }, { "name": "complementary and alternative therapy", "type": "PROCEDURE" }, { "name": "differentiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003514" }, { "nct_id": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GEP-NET", "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Tumor Disease", "Neuroendocrine Tumors", "Carcinoid", "Carcinoid Tumor", "Pancreatic NET" ], "interventions": [ { "name": "RYZ101", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Lanreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RayzeBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2022-03-24", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477576" }, { "nct_id": "NCT03147768", "title": "Laser Tissue Welding - Distal Pancreatectomy Sealing Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Tumor, Benign", "Pancreatic Neoplasms", "Pancreatic Adenocarcinoma", "Pancreatic Pseudocyst", "Pancreatic Neuroendocrine Tumor", "Pancreas; Insulinoma", "Pancreatic Cyst", "Pancreatic Teratoma", "Pancreatic Polypeptide Tumor", "Pancreatic Vipoma", "Pancreatic Cystadenoma", "Pancreas Injury", "Pancreatic Gastrinoma", "Pancreatic Glucagonoma" ], "interventions": [ { "name": "Distal Pancreatectomy Sealing Using LTW", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Laser Tissue Welding, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-01-01", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147768" }, { "nct_id": "NCT00001228", "title": "Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Islet Cell Adenoma", "Zollinger Ellison Syndrome" ], "interventions": [ { "name": "Interferon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "1988-10-25", "completion_date": "2007-09-06", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001228" }, { "nct_id": "NCT00001240", "title": "Evaluating Patients With Abnormal Levels of Gastric Acid", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Achlorhydria", "Gastrinoma", "Zollinger Ellison Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1989-01", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2008-03-05", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001240" }, { "nct_id": "NCT01155258", "title": "Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Hereditary Paraganglioma", "Male Breast Cancer", "Malignant Paraganglioma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pheochromocytoma", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Regional Pheochromocytoma", "Stage III Cervical Cancer", "Stage III Endometrial Carcinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Neuroendocrine Carcinoma of the Skin", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Uterine Sarcoma", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-06", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01155258" }, { "nct_id": "NCT04483349", "title": "Assessment of What Patients and Healthcare Providers Value", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 397, "start_date": "2020-06-11", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04483349" }, { "nct_id": "NCT01204476", "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrin-Producing Neuroendocrine Tumor", "Lung Carcinoid Tumor", "Metastatic Digestive System Neuroendocrine Tumor G1", "Pancreatic Glucagonoma", "Pancreatic Insulinoma", "Pancreatic Polypeptide Tumor", "Paraganglioma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Merkel Cell Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Somatostatin-Producing Neuroendocrine Tumor", "Stage III Merkel Cell Carcinoma", "Stage IV Merkel Cell Carcinoma", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-15", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204476" }, { "nct_id": "NCT00084461", "title": "Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Metastatic Gastrointestinal Carcinoid Tumor", "Pancreatic Polypeptide Tumor", "Pulmonary Carcinoid Tumor", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Regional Gastrointestinal Carcinoid Tumor", "Somatostatinoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084461" }, { "nct_id": "NCT00434109", "title": "Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumor", "Islet Cell Tumor" ], "interventions": [ { "name": "Sunitinib malate", "type": "DRUG" }, { "name": "Hepatic Artery Embolizations", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2006-11", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2012-09-14", "last_synced_at": "2026-07-23T22:30:55.523Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00434109" } ] }